NCT01273402View on ClinicalTrials.gov

Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

August 31, 2018

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

TF2/IMP288

TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.

Trial Locations (1)

20057

Georgetown University Medical Center, Washington D.C.

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gilead Sciences

INDUSTRY